Halozyme Therapeutics, Inc.


Oct 19, 09

NEW STORY
08:00 ET Halozyme to Present at the BIOCOM Investor Conference on October 26

 
Jan 06, 09

08:00 ET Halozyme Receives $5.5 Million Payment From Baxter

 
Jan 05, 09

08:00 ET Phase III Trial Begins for GAMMAGARD LIQUID Plus rHuPH20 in Primary Immunodeficiency Patients

 
Dec 10, 08

08:00 ET Halozyme Therapeutics Begins Phase 1 Clinical Trial of Bisphosphonate Administered With rHuPH20 Enzyme

 
Dec 08, 08

08:00 ET Halozyme Therapeutics Announces Roche Begins Phase 1 Clinical Trial and Selects Fourth Exclusive Biologic Target

 
Nov 06, 08

16:05 ET Halozyme Therapeutics Reports 2008 Third Quarter Financial Results

 
Nov 03, 08

07:00 ET Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients

 
Oct 30, 08

13:00 ET Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results

 
Oct 22, 08

08:00 ET Halozyme Therapeutics to Present at Upcoming Investor Conferences

 
Oct 01, 08

08:00 ET Halozyme Therapeutics to Host Research Day for Investors and Analysts

 
Sep 23, 08

08:00 ET Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development

 
Sep 10, 08

08:00 ET Halozyme Therapeutics to Present at Upcoming Investor Conferences

 
Sep 02, 08

08:00 ET Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives

 
Aug 08, 08

08:00 ET Halozyme Therapeutics Reports 2008 Second Quarter Financial Results

 
Jul 31, 08

16:30 ET Halozyme Therapeutics to Hold Pipeline Update Conference Call on August 8

 
Jul 22, 08

08:00 ET Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models

 
Jun 30, 08

16:39 ET Halozyme Therapeutics Announces That Chemophase Meets Primary Endpoint in Phase I/IIa Clinical Trial

 
Jun 18, 08

08:00 ET Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference

 
Jun 09, 08

08:00 ET Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability

 
May 19, 08

16:21 ET Halozyme Therapeutics Presents Pre-Clinical Studies on Dermal Remodeling With HTI-501, a Lysosomal Proteinase

 
May 08, 08

17:00 ET Halozyme Therapeutics Reports 2008 First Quarter Financial Results

 
May 06, 08

08:00 ET Halozyme Therapeutics to Present at Upcoming Investor Conferences

 
May 01, 08

08:00 ET Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9

 
Apr 16, 08

08:00 ET Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference

 
Apr 15, 08

08:00 ET Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference

 
Mar 13, 08

17:00 ET Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results

 
Mar 12, 08

08:00 ET Halozyme Therapeutics to Present at the Cowen and Company 28th Annual Health Care Conference

 
Mar 10, 08

16:15 ET Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences

 
Mar 07, 08

08:00 ET Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14

 
Feb 05, 08

08:00 ET Halozyme Therapeutics to Present at the BIO CEO and Investor Conference and the Roth Growth Stock Conference

 
Jan 08, 08

08:00 ET Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex

 
Nov 19, 07

08:00 ET Halozyme Therapeutics to Present at Lazard Capital Markets Fourth Annual Healthcare Conference

 
Nov 14, 07

16:15 ET Halozyme Therapeutics Amends Stockholder Rights Plan

 
Nov 13, 07

16:15 ET Halozyme Therapeutics Names Matthew R. Hooper Vice President, General Counsel

 
Nov 12, 07

16:15 ET Halozyme Therapeutics Added to Nasdaq Biotech Index

 
Nov 08, 07

16:30 ET Halozyme Therapeutics Reports 2007 Third Quarter Financial Results

 
Nov 01, 07

16:31 ET Halozyme Therapeutics to Hold Business Update Conference Call on November 9

 
Sep 25, 07

16:15 ET Halozyme Therapeutics Completes Enrollment in Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer

 
Sep 13, 07

16:15 ET Halozyme Therapeutics to Present at UBS 2007 Global Life Sciences Conference

 
Aug 28, 07

08:00 ET Halozyme Therapeutics to Present at Roth Capital Partners 2007 New York Conference

 
Aug 09, 07

16:16 ET Halozyme Therapeutics Reports 2007 Second Quarter Financial Results

 
Aug 02, 07

08:00 ET Halozyme Therapeutics to Hold Business Update Conference Call on August 10

 
Jul 17, 07

08:00 ET Halozyme Therapeutics Names Walter H. Bee, PhD Vice President, Preclinical Development

 
Jul 09, 07

16:15 ET Halozyme Therapeutics' Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society

 
May 31, 07

08:00 ET Halozyme Therapeutics Announces Closing of $32.1 Million Private Financing

 
May 16, 07

08:00 ET Halozyme Therapeutics Names Randal J. Kirk and Kathryn E. Falberg to Board of Directors

 
May 14, 07

16:15 ET Halozyme Therapeutics and Roche to Deliver Joint Presentation at SCRIP Conference:

 
May 10, 07

16:15 ET Halozyme Therapeutics Reports 2007 First Quarter Financial Results

 
May 07, 07

08:00 ET Halozyme Therapeutics to Hold Business Update Conference Call on May 11

 
May 02, 07

08:00 ET Halozyme Therapeutics to Present at May Investment Conferences

 
Apr 30, 07

08:00 ET Halozyme Therapeutics Announces Nasdaq Global Market Listing Approval

 
Apr 24, 07

08:00 ET Halozyme Therapeutics Announces $32.1 Million Private Financing

 
Mar 13, 07

17:00 ET Halozyme Therapeutics Adopts SEC Rule 10b5-1 Policy

 
Mar 08, 07

08:00 ET Halozyme Therapeutics Reports Fourth Quarter and Year End 2006 Financial Results

 
Mar 07, 07

08:00 ET Halozyme Therapeutics to Present at the Cowen & Company 27th Annual Health Care Conference

 
Mar 06, 07

08:00 ET Halozyme Therapeutics to Hold 2006 Fourth Quarter and Year End Conference Call on March 8

 
Feb 14, 07

08:00 ET Halozyme and Baxter Expand Global HYLENEX Collaboration

 
Feb 13, 07

08:00 ET Halozyme therapeutics to Present at the Roth Capital Partners 19th Annual OC Conference

 
Jan 22, 07

08:00 ET Halozyme Therapeutics Releases Results of Enhanze Technology Clinical Trial to Improve the Subcutaneous Absorption of a Large Protein Molecule Therapeutic

 
Jan 03, 07

08:00 ET Halozyme Therapeutics to Present at the JPMorgan 25th Annual Healthcare Conference

 
Nov 27, 06

08:00 ET Halozyme Therapeutics Completes Enrollment of Enhanze Technology Clinical Trial to Improve the Subcutaneous Absorption of a Large Protein Molecule Therapeutic

 
Nov 20, 06

08:00 ET Halozyme Therapeutics to Present at the Lazard Capital Markets Third Annual Life Sciences Conference

 
Nov 09, 06

16:05 ET Halozyme Therapeutics Reports Third Quarter 2006 Financial Results

 
Nov 08, 06

16:00 ET Halozyme Therapeutics Names William Fallon Vice President, Manufacturing & Operations

 
Nov 01, 06

13:55 ET Halozyme Therapeutics to Present at the Rodman and Renshaw 8th Annual Healthcare Conference

 
Oct 26, 06

08:00 ET New Survey Reveals Most Patients Are Unaware That Slaughterhouse-Derived Animal Products Are Used in a Majority of IVF Procedures

 
Oct 12, 06

08:00 ET Halozyme Therapeutics to Present at the 2006 Bio InvestorForum

 
Oct 10, 06

08:00 ET Halozyme Therapeutics Completes Enrollment of Infuse-Morphine Clinical Trial

 
Sep 19, 06

08:00 ET Halozyme Therapeutics to Present at the Noble Financial Small Cap Conference

 
Sep 13, 06

08:00 ET Halozyme Therapeutics Completes Call of Second Tranche of Warrants From January 2004 Financing

 
Aug 29, 06

08:00 ET Halozyme Therapeutics to Present at the Roth 2006 New York Conference

 
Aug 10, 06

08:00 ET Halozyme Therapeutics Reports Second Quarter 2006 Financial Results

 
Aug 09, 06

08:00 ET Halozyme Therapeutics Calls Second Tranche of Warrants From January 2004 Financing

 
Aug 08, 06

08:00 ET Halozyme Therapeutics Initiates First Enhanze Technology Clinical Trial to Improve the Subcutaneous Absorption of a Large Molecule Protein Therapeutic

 
Aug 07, 06

16:00 ET Halozyme Therapeutics to Hold 2006 Second Quarter Conference Call on August 10

 
Jul 31, 06

08:00 ET Halozyme Therapeutics Names Connie Matsui to Board of Directors

 
Jul 26, 06

08:00 ET Halozyme Therapeutics Names Robert Little Chief Commercial Officer

 
Jul 12, 06

16:00 ET Halozyme Therapeutics Announces New Studies From HTI-101 Presented at Proteoglycan Research Conference

 
Jun 27, 06

08:00 ET Halozyme and Baxter Announce Availability of Hylenex for Subcutaneous Delivery of Medications and Fluids

 
Jun 20, 06

12:24 ET Halozyme Therapeutics to Present at the Jefferies Life Sciences Conference

 
Jun 01, 06

21:39 ET Halozyme Therapeutics Presents Preclinical and Pharmacokinetic Data on the Subcutaneous Delivery of Antibodies With Enhanze Technology at the 2006 IBC Antibody Conference

 
May 23, 06

08:00 ET Halozyme Therapeutics Announces FDA 510(k) Clearance for MediCult's SynVitro Cumulase Product

 
May 10, 06

08:00 ET Halozyme Therapeutics Reports First Quarter 2006 Financial Results

 
May 09, 06

08:00 ET Halozyme Therapeutics to Present at the Rodman & Renshaw 3rd Annual Global Healthcare Conference

 
May 08, 06

08:00 ET Halozyme Therapeutics Adopts Stockholder Rights Plan

 
May 04, 06

08:00 ET Halozyme Therapeutics Announces 22% Increase in IVF ICSI Fertilization Rates in Eggs Treated With Cumulase Versus Bovine Extract

 
Apr 26, 06

08:00 ET Halozyme Therapeutics Initiates Chemophase Phase I/IIa Clinical Trial for Superficial Bladder Cancer

 
Apr 20, 06

08:00 ET Halozyme Therapeutics Receives Approximately $1.9 Million From Exercise of Warrants

 
Apr 04, 06

08:18 ET Halozyme Therapeutics Presents Preclinical and Phase I Pharmacokinetic Data for Chemophase at the 2006 American Association for Cancer Research (AACR) Annual Meeting

 
Mar 28, 06

08:04 ET Halozyme Therapeutics to Present Preclinical, Toxicology and Phase I Data at the 2006 American Association for Cancer Research (AACR) Annual Meeting

 
Mar 23, 06

08:01 ET Halozyme Therapeutics Reports Fourth Quarter and Year End 2005 Financial Results

 
Mar 20, 06

08:03 ET Halozyme Therapeutics to Hold 2005 Fourth Quarter and Year End Conference Call on March 23

 
Mar 06, 06

08:01 ET Halozyme Therapeutics Completes Enrollment of Chemophase Phase I Clinical Trial for Superficial Bladder Cancer

 
Mar 02, 06

08:03 ET Halozyme Therapeutics to Present at the Cowen & Co. 26th Annual Health Care Conference

 
Feb 15, 06

16:00 ET Halozyme Therapeutics to Present at Roth Capital Partners 18th Annual OC Conference

 
Feb 13, 06

08:02 ET Halozyme Therapeutics Announces Notice of Allowance for Patent Claims to Second Human Enzyme

 
Feb 08, 06

16:07 ET Halozyme Therapeutics and Baxter Release Results From the INFUSE-LR Study

 
Feb 02, 06

08:00 ET Halozyme Therapeutics Initiates Clinical Trial of Subcutaneous Morphine With Hylenex

 
Jan 25, 06

08:03 ET Halozyme Therapeutics to Present at Brean Murray, Carret Small Cap Institutional Investor Conference 2006

 
Jan 24, 06

08:02 ET Halozyme Therapeutics Completes Enrollment of INFUSE-LR, a Hylenex Clinical Trial of Subcutaneous Hydration

 
Dec 21, 05

08:01 ET Halozyme Therapeutics Announces New Chairman

 
Dec 15, 05

08:02 ET Halozyme Therapeutics Initiates Hylenex Clinical Trial of Subcutaneous Hydration

 
Dec 13, 05

18:49 ET Halozyme Therapeutics Obtains an Additional Commitment for $1.4 Million in a Registered Direct Offering of Common Stock

 
08:03 ET Halozyme Therapeutics to Raise $16.1 Million in Registered Direct Offering of Common Stock

 
Dec 05, 05

08:08 ET Halozyme Therapeutics and Baxter Healthcare Corporation Announce FDA Approval of Hylenex

 
Nov 11, 05

08:00 ET Halozyme Therapeutics Reports Third Quarter 2005 Financial Results

 
Nov 04, 05

14:01 ET Halozyme Therapeutics to Hold Third Quarter 2005 Conference Call on November 11

 
Oct 31, 05

16:08 ET Halozyme Therapeutics to Present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference

 
Oct 27, 05

16:38 ET Halozyme Therapeutics Initiates Chemophase Phase I Clinical Trial for Superficial Bladder Cancer - First Patients Treated

 
Sep 27, 05

08:02 ET Halozyme Therapeutics Presents Novel Stroke Data at the 2005 American Neurological Association Annual Meeting

 
Sep 26, 05

08:02 ET Halozyme Therapeutics Provides Update on Hylenex New Drug Application

 
Aug 29, 05

08:01 ET Halozyme Therapeutics to Present at the Roth Capital Partners New York Conference

 
Aug 11, 05

08:03 ET Halozyme Therapeutics Receives FDA Clearance to Initiate Chemophase Clinical Trial

 
Aug 08, 05

08:07 ET Halozyme Therapeutics and Baxter Healthcare Corporation Expand Relationship to Include European Union

 
07:45 ET Halozyme Therapeutics Reports Second Quarter 2005 Financial Results

 
Jul 27, 05

16:19 ET Halozyme Therapeutics to Hold Second Quarter 2005 Conference Call on August 8

 
Jul 20, 05

08:07 ET Halozyme Therapeutics Names Former Assistant Secretary of Defense, Sue Bailey, to Scientific Advisory Board

 
Jul 06, 05

08:05 ET Halozyme Therapeutics Names Steve Thornton to Board of Directors

 
Jun 30, 05

08:05 ET Halozyme Therapeutics Announces Submission of Investigational New Drug Application for Chemophase

 
Jun 22, 05

08:01 ET Halozyme Therapeutics and Reproductive Biology Associates Announce New Clinical Data in IVF: Significantly Increased Fertilization Rates With Cumulase

 
Jun 21, 05

16:15 ET Halozyme Therapeutics Announces Clinical Safety and Tolerability Data for rHuPH20 Hyaluronidase Presented at BIO 2005

 
Jun 20, 05

08:06 ET Halozyme Therapeutics Announces Launch of Cumulase for In Vitro Fertilization

 
Jun 13, 05

12:41 ET Halozyme Therapeutics Scheduled to Join the New Russell Microcap Index

 
May 26, 05

12:28 ET Halozyme Therapeutics Announces FDA Acceptance of Hylenex NDA

 
May 25, 05

12:50 ET Halozyme Therapeutics to Present at Friedman Billings Ramsey 9th Annual Growth Investor Conference

 
May 13, 05

08:01 ET Halozyme Therapeutics Reports First Quarter 2005 Financial Results

 
May 05, 05

14:18 ET Halozyme Therapeutics to Hold First Quarter 2005 Conference Call on May 13

 
May 04, 05

12:46 ET Halozyme Therapeutics' Enhanze Technology Featured in Drug Delivery Technology

 
May 02, 05

08:01 ET Halozyme Therapeutics Presents rHuPH20 Hyaluronidase Preclinical Data at the 2005 Association for Research in Vision and Ophthalmology Annual Meeting

 
Apr 27, 05

12:30 ET Halozyme Therapeutics to Present at Rodman & Renshaw Techvest Healthcare Conference

 
Apr 19, 05

16:31 ET Halozyme Therapeutics Presents rHuPH20 Hyaluronidase Preclinical Data at the 2005 American Association for Cancer Research

 
08:03 ET Halozyme Therapeutics Receives FDA 510(k) Clearance for Cumulase

 
Apr 18, 05

16:12 ET Halozyme Therapeutics Announces rHuPH20 Hyaluronidase Preclinical Data Presented at the 2005 American Society of Cataract & Refractory Surgery Symposium and Congress

 
Apr 12, 05

08:04 ET Halozyme Therapeutics Adds Vice President of Clinical Development and Medical Affairs to Management Team

 
Apr 06, 05

08:02 ET Halozyme Therapeutics Receives FDA Priority Review for Enhanze SC NDA

 
Mar 30, 05

16:15 ET Halozyme Therapeutics and Baxter Healthcare Corporation Expand Relationship to Include Development and Supply Agreement

 
Mar 28, 05

08:00 ET Halozyme Therapeutics Files NDA for Enhanze SC

 


Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2009 PR Newswire Association LLC. ALL Rights Reserved.
A United Business Media company.